PCI Biotech to present at DNB Nordic Healthcare Conference 2021
Oslo (Norway), 14 December 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that it has been invited to present at the DNB Nordic Healthcare Conference 2021, an Oslo based online event hosted by DNB.
On Thursday, 16 December 2021 at 11:10 (CET), Dr. Per Walday, CEO, will present an overview of PCI Biotech’s proprietary platform technology via a general company presentation. The Company is also available for 1:1 meetings with potential partners and investors.
The presentation slides will be made available on PCI Biotech’s website (www.pcibiotech.com) under “Other presentations”.
Contact information:
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429
About PCI Biotech
PCI Biotech is a biopharmaceutical late-stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in perihilar and distal bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Forløb af ordinær generalforsamling i ØK - Selskabsmeddelelse nr. 4/202426.4.2024 12:57:02 CEST | pressemeddelelse
26. april 2024 Den 26. april 2024 kl. 11.00 afholdtes ordinær generalforsamling i Det Østasiatiske kompagni A/S, i Asia House, Indiakaj 16, 2100 København Ø. På den ordinære generalforsamling blev følgende dagsordenspunkter behandlet: a. Bestyrelsens beretning blev taget til efterretning. b. Årsrapporten for 2023 blev godkendt. c. Der blev meddelt decharge for bestyrelsen og direktionen. d. Anvendelse af årets resultat i overensstemmelse med den godkendte årsrapport blev godkendt. e. Præsentation af vederlagsrapporten for 2023. f. Bestyrelsens honorar for 2024 blev vedtaget. g. Ole Steffensen, Martin Thaysen og Kresten M. Valdal blev valgt som medlemmer til bestyrelsen. h. KPMG P/S blev genvalgt som selskabets revisor. i. Bestyrelsen bemyndigedes til at lade selskabet erhverve egne aktier. j. Forslag fra bestyrelsen om: Selskabets vederlagspolitik blev godkendt.Forslaget om ændring af selskabets navn til ”Det Østasiatiske Kompagni A/S” og optagelse af binavne blev vedtaget. k. Dirigent
Resolutions of Harvia Plc's Annual General Meeting on 26 April 202426.4.2024 12:30:00 CEST | Press release
STOCK EXCHANGE RELEASE 26 April 2024 at 1.30 p.m. EEST Resolutions of Harvia Plc's Annual General Meeting on 26 April 2024 Harvia Plc’s Annual General Meeting, held today on 26 April 2024, approved the financial statements and discharged the members of the Board of Directors and the company’s CEO from liability for the financial year 2023. The Annual General Meeting approved in an advisory decision the remuneration report for governing bodies. The Annual General Meeting resolved to reject the revised remuneration policy for the company’s governing bodies. The resolution made is advisory. Use of the profit shown on the balance sheet and the distribution of dividend The Annual General Meeting approved the Board of Directors’ proposal that EUR 0.68 per share be paid as dividend and that the remainder of the distributable funds be transferred to shareholders’ equity. The dividend is paid in two instalments. The first instalment, EUR 0.34 per share, will be paid to shareholders who are regi
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 202426.4.2024 12:16:38 CEST | Press release
Bagsværd, Denmark, 26 April 2024 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred. Referring to Company Announcement no 32/2024 dated 24 April 2024, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 26 April 2024. Number of shares (of DKK 0.10 each)Share capital (nominal value, DKK)Number of votes1 A shares 1,074,872,000 107,487,200 107,487,200,000 B shares 3,390,128,000 339,012,800 33,901,280,000 Total 4,465,000,000 446,500,000 141,388,480,000 1 Each A share of DKK 0.01 carries 10 votes, whereas each B share of DKK 0.01 carries one vote. Thus, each A share of DKK 0.10 carries 100 votes and each B share of DKK 0.10 (the present denomination of the company's shares) carries 10 votes. Treasury shares are included in
Amendment of the terms concerning Convertible Bonds 2021/1, 2021/2, 2021/3, 2021/4 and 2022/1 issued by Digitalist Group Plc26.4.2024 12:00:00 CEST | Press release
Digitalist Group Oyj Stock Exchange Release 26 April 2024 at 13:00 Amendment of the terms concerning Convertible Bonds 2021/1, 2021/2, 2021/3, 2021/4 and 2022/1 issued by Digitalist Group Plc and the option rights and other special rights pursuant to Chapter 10 section 1(2) of the Limited Liability Companies Act attached to them 1. Convertible Bonds 2021/1, 2021/3 and 2022/1 directed to Turret Oy Ab Digitalist Group Plc ("Digitalist Group" or the “Company") and Turret Oy Ab ("Turret") have signed agreements to amend the terms (the “Terms”) of the Convertible Bonds 2021/1, 2021/3, and 2022/1 and the option rights and other special rights (the “Special Rights”) pursuant to Chapter 10 section 1(2) of the Limited Liability Companies Act attached to them issued to Turret. The Annual General Meeting of Digitalist Group 25 April 2024 resolved on the amendments to the Terms of the Convertible Bonds 2021/1, 2021/3, and 2022/1 issued to Turret. Turret is the largest shareholder of the Company. T
NetBet Casino slår sig sammen med Habanero26.4.2024 11:33:27 CEST | pressemeddelelse
COPENHAGEN, Denmark, April 26, 2024 (GLOBE NEWSWIRE) -- NetBet Danmark har indgået et partnerskab med iGaming-virksomheden Habanero. Dette samarbejde er en del af NetBets mission om at forbedre spiloplevelsen for danske spillere ved at øge antallet af tilgængelige spil. Siden grundlæggelsen i 2010 har Habanero etableret sig på et konkurrencepræget marked og er blevet shortlistet til flere priser ved Asia Gaming Awards i 2016. Som en del af NetBet Danmarks partnerskab med Habanero kan spillerne nyde en række fremragende spil - såsom Legendary Beasts, Zeus Deluxe og Meow Janken - samt andre spil fra online casinoudbyderen. NetBet Danmarks PR-manager, Claudia Georgevici, siger: "NetBet sigter mod at give vores spillere den bedst mulige spiloplevelse. Habanero har et bredt udvalg af fremragende spilleautomater og bordspil, og vi er begejstrede for, at vores kunder selv kan opleve deres spil som en del af denne spændende aftale." NetBet-spillere kan nu udforske de spændende nye spil fra Hab